Primary Immuno-Deficiencies Clinical Trial
Official title:
Evaluation of the Efficacy of the Sequencing Method by Gene-panel, Compared to the Reference Sanger Method, on Patients With Primary Immuno-deficiencies, and Who Need a Genetic Diagnosis.
In order to accelerate the identification of genes responsibles of PID, and to improve the diagnosis of PID, the research team would like to validate a rapid and targeted method of high-throughput sequencing, on 301 genes, known to be involved in PID.
The Primary Immuno-Deficiencies (PID) are a set of rare diseases (estimated incidence of
1/5000). Today, more than 320 PID are described, and for 301 of them, the genetic cause has
been identified, which underlines the huge diversity of all PID.
The genetic diagnosis of PID is very important for the comprehension of PID physiopathology,
their treatment and the genetic patient information.
The characterisation of the clinical and immunological phenotype of patients allowed to
identify a known morbid gene in 30% of cases, but for other patients, the genetic cause
remains unknown, due to, inter alia, the lack of efficient tools for genetic exploration.
In this context, each year, around 600 French and foreign patients are explored at the Necker
hospital CEDI (Center for Immuno-Deficiencies Explorations), for whom are identified, in 30%
of cases, a known genetic cause.
Their treatment and the diagnosis of these patients is slow, partially because these studies
are dependants of research fundings. In addition, in the current practice, the investigators
sometimes discover incidental findings via the non-targeted high throughput genetic analyzes.
The aim of the gene-panel is to improve the diagnosis procedures of these known diseases, by
generalizing a rapid and targeted method of sequencing, on 301 genes, known to be involved in
PID.
;